Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Amgen is a global biotechnology company operating in a single segment: human therapeutics. The company discovers, develops, manufactures, and markets products in nephrology, supportive cancer care, and inflammatory disease. Principal products include EPOGEN, Aranesp, Neulasta, NEUPOGEN, and ENBREL (co-promoted with Wyeth in the U.S. and Canada).
Key Financial Metrics
| Metric (in millions) | 2004 | 2003 | 2002 |
|---|---|---|---|
| Total Revenues | $10,550 | $8,356 | $5,523 |
| Product Sales | $9,977 | $7,868 | $4,991 |
| Net Income | $2,363 | $2,259 | $(1,392) |
| Diluted EPS | $1.81 | $1.69 | $(1.21) |
| Operating Income | $3,348 | $3,091 | $(785) |
| Operating Margin (vs Product Sales) | 34% | 39% | N/A |
| Research & Development (R&D) | $2,028 | $1,655 | $1,117 |
| IPR&D Write-off | $554 | $0 | $2,992 |
| Cash from Operations | $3,697 | $3,567 | $2,249 |
| Total Assets | $29,221 | $26,113 | $24,456 |
| Long-term Debt | $3,937 | $3,080 | $3,048 |
| Cash & Marketable Securities | $5,808 | $5,123 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 26% to $10.55 billion, driven primarily by sales growth in Aranesp (up 60%), ENBREL (up 46%), and Neulasta (up 39%). International product sales grew 54%.
- Acquisition Impact: Amgen acquired Tularik Inc. in August 2004 for approximately $1.5 billion. This resulted in a one-time non-cash charge of $554 million for the write-off of in-process research and development (IPR&D), which reduced operating income margins compared to 2003.
- Product Mix Shift: Cost of sales increased 29% due to higher sales volumes and a shift toward higher-cost products like ENBREL. R&D expenses rose 23% due to staff additions from Tularik and increased clinical trial costs.
- Debt Structure: In November 2004, Amgen issued $2 billion in senior notes (4.00% due 2009 and 4.85% due 2014). Proceeds were used for stock repurchases and general corporate purposes.
Guidance, Outlook, and Risks
- Reimbursement Risks (MMA): The Medicare Modernization Act (MMA) is expected to negatively impact reimbursement rates for key products (Aranesp, Neulasta, NEUPOGEN, EPOGEN) starting in 2005. New payment methodologies (ASP+6%) are projected to lower rates compared to 2004.
- Supply Constraints: ENBREL sales growth may be constrained by manufacturing capacity. Amgen relies on third-party manufacturers (BI Pharma, Genentech) and its own Rhode Island facility. New capacity is expected to come online in 2005.
- Patent Expirations: The European patent for erythropoietin expired in December 2004, and the G-CSF patent expires in August 2006, potentially exposing Aranesp and NEUPOGEN to biosimilar competition in Europe.
- Accounting Changes: Amgen plans to adopt SFAS No. 123R in July 2005, which will require expensing stock options. The estimated after-tax impact for 2005 is $170 million to $220 million.
- Legal Proceedings: The company faces ongoing litigation regarding Average Wholesale Price (AWP) reporting and patent disputes (e.g., Transkaryotic Therapies), though management does not believe these will have a material adverse effect on annual financial statements.
Key Facts for Investor Verification
- Reimbursement Impact: Verify the actual impact of the MMA reimbursement changes on 2005 sales volumes and pricing for EPOGEN, Aranesp, Neulasta, and NEUPOGEN.
- ENBREL Supply: Monitor the timeline for FDA approval of the new Rhode Island manufacturing facility and the capacity ramp-up of third-party suppliers to ensure demand is met.
- Stock Repurchases: As of December 31, 2004, $5.97 billion remained available for stock repurchases under Board authorizations.
- Convertible Notes Put Option: Note that holders of $3.95 billion in Convertible Notes exercised a put option in March 2005, resulting in a $1.175 billion cash repurchase.
- Product Pipeline: Track the progress of key pipeline candidates, particularly AMG 162 (osteoporosis/bone metastases) and panitumumab (colorectal cancer), which are in Phase 3 trials.